Phase 1 study of safety and tolerability of an oral contraceptive containing low‐dose ethinyl oestradiol combined with glecaprevir/pibrentasvir treatment in healthy premenopausal women
Journal of Viral Hepatitis · 2024
DOI: 10.1111/jvh.13946 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Viral Hepatitis, 2024. Verfasst von Dee-Dee Shiller und 7 weiteren Autor:innen. Beteiligte Einrichtung: AbbVie, Inc., North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Benzimidazoles, Quinoxalines, Premenopause, Ethinyl Estradiol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Glecaprevir/pibrentasvir (GLE/PIB) is an approved guideline‐recommended chronic hepatitis C virus infection treatment. GLE/PIB coadministration with ethinyl oestradiol (EE) is not recommended in current labels owing to a Phase 1 study observing Grade ≥2 alanine aminotransferase (ALT) elevation in 2 out of 12 healthy women cotreated for 11 days with GLE/PIB and oral contraceptive (OC) containing 35 μg/250 μg EE/norgestimate. No Grade ≥2 elevation was observed with low‐dose (20 μg) EE ( n = 14). This Phase 1 study examined safety/tolerability of GLE/PIB coadministered with an OC containing low‐dose EE using a larger sample size and longer treatment duration. Healthy premenopausal women were treated with EE/levonorgestrel alone (20/100 μg, Cycles 1–2), followed by coadministration with GLE/PIB (300/120 mg; Cycles 3–4). A safety criterion of special interest was a confirmed Grade ≥2 ALT elevation (>3× upper normal limit). Adverse events (AEs) and study drugs concentrations were examined. Of 85 enrolled women, 72 initiated combined GLE/PIB + EE/levonorgestrel treatment, 66 completed the study and 19 discontinued prematurely (non‐safety reason, n = 16; AE [deemed unelated to GLE/PIB], n = 3). No participant met the safety criterion of special interest of confirmed Grade ≥2 ALT elevation. No serious/Grade ≥3 AEs were reported. Study drug concentrations were within the expected ranges. GLE/PIB in combination with an OC containing low‐dose EE was generally well tolerated with no confirmed Grade ≥2 ALT elevation and no evidence of drug‐induced liver injury. No pattern to the reported AEs and no new safety issues were identified. This was a Phase 1 study of healthy volunteers, not a registered clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AbbVie, Inc., North Chicago, Illinois, USA.
- PPD Phase 1 Clinic, Austin, Texas, USA.
ORCID-Profile: Craig Boyle
Förderung
- AbbVie
Zitieren
APA
Shiller, D. D., Yao, B. B., Chen, M. J., Orejudos, A., Mostafa, N. M., Marcinak, J. F., Burroughs, M., & Boyle, C. (2024). Phase 1 study of safety and tolerability of an oral contraceptive containing low‐dose ethinyl oestradiol combined with glecaprevir/pibrentasvir treatment in healthy premenopausal women. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13946
Vancouver
Shiller DD, Yao BB, Chen MJ, Orejudos A, Mostafa NM, Marcinak JF, et al. Phase 1 study of safety and tolerability of an oral contraceptive containing low‐dose ethinyl oestradiol combined with glecaprevir/pibrentasvir treatment in healthy premenopausal women. Journal of Viral Hepatitis. 2024. doi:10.1111/jvh.13946
BibTeX
@article{Shiller2024,
author = {Shiller, Dee-Dee and Yao, Betty B and Chen, Mong-Jen and Orejudos, Amelia and Mostafa, Nael M and Marcinak, John F and Burroughs, Margaret and Boyle, Craig},
title = {Phase 1 study of safety and tolerability of an oral contraceptive containing low‐dose ethinyl oestradiol combined with glecaprevir/pibrentasvir treatment in healthy premenopausal women},
journal = {Journal of Viral Hepatitis},
year = {2024},
doi = {10.1111/jvh.13946}
}
EUVIMED